Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.So what's the real story here? Did the trial actually flop, or is the market getting it totally wrong? The answer to both those questions is, "No." Let's explore what's going on in more detail so that you'll know how it affects your plans for the stock.On Dec. 20, the bull thesis for Novo Nordisk stock took a massive hit. In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by targeting a cellular receptor called GLP-1.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool